ProCE Banner Activity

KEYNOTE-006: Final OS Analysis of Pembrolizumab vs Ipilimumab for Advanced Melanoma

Slideset Download
Conference Coverage
Median OS not reached for pembrolizumab at median follow-up of 23 months, with continuing durable responses and favorable safety profile.

Released: June 13, 2016

Expiration: June 12, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals